Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015
|
|
- Andrea Barrett
- 8 years ago
- Views:
Transcription
1 Moda Health Plan, Inc. Medical Necessity Criteria Subject: Actemra (tocilizumab) Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015 Approved: Mary Engrav, MD Date: 02/24/2016 Description: Actemra (tocilizumab) is a humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody that is approved to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Patients with rheumatoid arthritis have elevated IL-6 concentrations both in serum and in synovial fluid. Furthermore, IL-6 concentrations correlate with disease activity and joint damage. Criteria: CWQI HCS-0096 I. Actemra (tocilizumab) is considered medically necessary for 1 or more of the following indications: a. Rheumatoid Arthritis with ALL of the following: i. Adult patient (18 years or older); ii. Patient has been evaluated and screened for the presence of latent TB infection prior to initiating treatment iii. Documented moderate to severe active disease iv. Patient has had at least a three (3) month trial and failed previous therapy with one oral disease modifying anti-rheumatic agent (DMARD) such as methotrexate, Imuran, Ridaura, Plaquenil, Cuprimine, Asulfidine, Arave v. May be used alone or in combination with MTX and 1 or more of the following: 1. Patient must try and have an inadequate response, contraindication, or intolerance to at least a three (3) month trial of Enbrel AND Humira 2. Patient is continuing treatment b. Systemic Juvenile Idiopathic Arthritis (SJIA) with ALL of the following: i. Patient is over the age of 2 ii. Patient has been evaluated and screened for the presence of latent TB infection prior to initiating treatment; and iii. Patient has active SJIA; and iv. Patient has had at least a three (3) month trial and failed previous therapy with one oral disease modifying anti-rheumatic agent (DMARD) such as methotrexate, Arave or glucocorticoids and
2 v. Only approved for IV formulation (will not be approved for subcutaneous (SC) formulation (Actemra 162 mg/0.9 ml pre-filled syringe). vi. May be used alone or in combination with MTX and 1 or more of the following: vii. Patient must try and have an inadequate response, contraindication, or intolerance to at least a three (3) month trial of Enbrel AND Humira viii. Patient is continuing treatment c. Polyarticular Juvenile Idiopathic Arthritis (PJIA) with ALL of the following: i. Patient is over the age of 2; and ii. Patient has been evaluated and screened for the presence of latent TB infection prior to initiating treatment; and iii. Patient has active PJJIA; and iv. Patient has had at least a three (3) month trial and failed previous therapy with one oral disease modifying anti-rheumatic agent (DMARD) such as methotrexate, Arave or glucocorticoids; and v. May be used alone or in combination with MTX; and vi. Only approved for IV formulation (will NOT be approved for subcutaneous (SC) formulation (Actemra 162 mg/0.9 ml pre-filled syringe) and 1 or more of the following: 1. Patient must try and have an inadequate response, contraindication, or intolerance to at least a three (3) month trial of Enbrel AND Humira; OR 2. Patient is continuing treatment d. Castleman s Disease will be covered when ALL of the following are met: i. Actemra is used as a single agent and 1 or more of the following: 1. Unicentris disease and ALL of the following: a. Patient is HIV (-) and HSVS (-) b. Used as second line therapy c. Patient has relapsed and/or refractory disease 2. Multicentris Disease and ALL of the following: a. Used as second line or later therapy b. Patient has relapsed, refractory and/or progressive disease e. Renewal of tocilizumab will be covered if ALL of the following are met: i. Patient continues to meet above criteria; and ii. Disease response as indicated by improvement in signs and symptoms compared to baseline such as the number of tender and swollen joint counts; and iii. Absence of unacceptable toxicity from the drug; and iv. Ongoing monitoring for TB II. Exclusions: a. Tocilizumab (Actemra) should not be administered to patients with known hypersensitivity to Actemra b. Tocilizumab (Actemra) is not medically indicated for diagnoses not FDA approved c. All indications not described in criteria are not covered and may be considered experimental or investigational.
3 III. Dosage and Administrations: Indication Adult Rheumatoid Arthritis (IV) Adult Rheumatoid Arthritis (SC) (wt<100kg Adult Rheumatoid Arthritis (SC) (wt 100kg) Polyarticular Juvenile Idiopathic Arthritis (IV) (wt 30 kg) Polyarticular Juvenile Idiopathic Arthritis (IV) (wt < 30 kg) Systemic Juvenile Idiopathic Arthritis (IV) (wt 30 kg) Systemic Juvenile Idiopathic Arthritis (IV) (wt < 30 kg) Dose 4 mg/kg 8 mg/kg IV every 4 weeks 162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response 162 mg administered subcutaneously every week 8 mg/kg IV every 4 weeks 10 mg/kg IV every 4 weeks 8 mg/kg IV every 2 weeks 12 mg/kg IV every 2 weeks Jcode: J Actemra (Genentech) 80 mg, 200 mg, 400 mg IV Injection: 1 billable unit = 1mg NDC: Actemra 80 mg/4ml vial xx (Genentech) Actemra 200mg/10ml vial xx (Genentech) Actemra 400mg/20ml vial xx (Genentech) Actemra 162mg/0.9ml pre-filled syringe xx (Genentech) IV. Dosing Limits: Quantity Limit (max daily dose) (Pharmacy Benefit): Actemra 162 mg/0.9 ml pre-filled syringe: 4 syringes every 28 days Max Units (per dose and over time) (Medical Benefit): Rheumatoid Arthritis Male: 800 billable units every 28 days Female: 800 billable units every 28 days Systemic Juvenile Idiopathic Arthritis Male: 800 billable units every 14 days Female: 800 billable units every 14 days Polyarticular Juvenile Idiopathic Arthritis Male: 800 billable units every 28 days Female: 800 billable units every 28 days
4 V. Information to be submitted with Pre-Authorization Request: a. Chart notes with documentation of diagnosis and confirmation of negative TB test. b. Laboratory reports ICD-10 Codes: ICD-10 D36.0 Benign neoplasm of lymph nodes ICD-10 Description M05.10 Rheumatoid lung disease with rheumatoid arthritis of unspecified site M Rheumatoid lung disease with rheumatoid arthritis of right shoulder M Rheumatoid lung disease with rheumatoid arthritis of left shoulder M Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder M Rheumatoid lung disease with rheumatoid arthritis of right elbow M Rheumatoid lung disease with rheumatoid arthritis of left elbow M Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow M Rheumatoid lung disease with rheumatoid arthritis of right wrist M Rheumatoid lung disease with rheumatoid arthritis of left wrist M Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist M Rheumatoid lung disease with rheumatoid arthritis of right hand M Rheumatoid lung disease with rheumatoid arthritis of left hand M Rheumatoid lung disease with rheumatoid arthritis of unspecified hand M Rheumatoid lung disease with rheumatoid arthritis of right hip M Rheumatoid lung disease with rheumatoid arthritis of left hip M Rheumatoid lung disease with rheumatoid arthritis of unspecified hip M Rheumatoid lung disease with rheumatoid arthritis of right knee M Rheumatoid lung disease with rheumatoid arthritis of left knee M Rheumatoid lung disease with rheumatoid arthritis of unspecified knee M Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot M Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot M Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot M05.19 Rheumatoid lung disease with rheumatoid arthritis of multiple sites M05.20 Rheumatoid vasculitis with rheumatoid arthritis of unspecified site M Rheumatoid vasculitis with rheumatoid arthritis of right shoulder M Rheumatoid vasculitis with rheumatoid arthritis of left shoulder M Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder
5 M Rheumatoid vasculitis with rheumatoid arthritis of right elbow M Rheumatoid vasculitis with rheumatoid arthritis of left elbow M Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow M Rheumatoid vasculitis with rheumatoid arthritis of right wrist M Rheumatoid vasculitis with rheumatoid arthritis of left wrist M Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist M Rheumatoid vasculitis with rheumatoid arthritis of right hand M Rheumatoid vasculitis with rheumatoid arthritis of left hand M Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand M Rheumatoid vasculitis with rheumatoid arthritis of right hip M Rheumatoid vasculitis with rheumatoid arthritis of left hip M Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip M Rheumatoid vasculitis with rheumatoid arthritis of right knee M Rheumatoid vasculitis with rheumatoid arthritis of left knee M Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee M Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot M Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot M Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot M05.29 Rheumatoid vasculitis with rheumatoid arthritis of multiple sites M05.30 Rheumatoid heart disease with rheumatoid arthritis of unspecified site M Rheumatoid heart disease with rheumatoid arthritis of right shoulder M Rheumatoid heart disease with rheumatoid arthritis of left shoulder M Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder M Rheumatoid heart disease with rheumatoid arthritis of right elbow M Rheumatoid heart disease with rheumatoid arthritis of left elbow M Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow M Rheumatoid heart disease with rheumatoid arthritis of right wrist M Rheumatoid heart disease with rheumatoid arthritis of left wrist M Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist M Rheumatoid heart disease with rheumatoid arthritis of right hand M Rheumatoid heart disease with rheumatoid arthritis of left hand M Rheumatoid heart disease with rheumatoid arthritis of unspecified hand M Rheumatoid heart disease with rheumatoid arthritis of right hip M Rheumatoid heart disease with rheumatoid arthritis of left hip
6 M Rheumatoid heart disease with rheumatoid arthritis of unspecified hip M Rheumatoid heart disease with rheumatoid arthritis of right knee M Rheumatoid heart disease with rheumatoid arthritis of left knee M Rheumatoid heart disease with rheumatoid arthritis of unspecified knee M Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot M Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot M Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot M05.39 Rheumatoid heart disease with rheumatoid arthritis of multiple sites M05.40 Rheumatoid myopathy with rheumatoid arthritis of unspecified site M Rheumatoid myopathy with rheumatoid arthritis of right shoulder M Rheumatoid myopathy with rheumatoid arthritis of left shoulder M Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder M Rheumatoid myopathy with rheumatoid arthritis of right elbow M Rheumatoid myopathy with rheumatoid arthritis of left elbow M Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow M Rheumatoid myopathy with rheumatoid arthritis of right wrist M Rheumatoid myopathy with rheumatoid arthritis of left wrist M Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist M Rheumatoid myopathy with rheumatoid arthritis of right hand M Rheumatoid myopathy with rheumatoid arthritis of left hand M Rheumatoid myopathy with rheumatoid arthritis of unspecified hand M Rheumatoid myopathy with rheumatoid arthritis of right hip M Rheumatoid myopathy with rheumatoid arthritis of left hip M Rheumatoid myopathy with rheumatoid arthritis of unspecified hip M Rheumatoid myopathy with rheumatoid arthritis of right knee M Rheumatoid myopathy with rheumatoid arthritis of left knee M Rheumatoid myopathy with rheumatoid arthritis of unspecified knee M Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot M Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot M Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot M05.49 Rheumatoid myopathy with rheumatoid arthritis of multiple sites M05.50 Rheumatoid myopathy with rheumatoid arthritis of unspecified sites M Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder M Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder
7 M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder M Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow M Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow M Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist M Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist M Rheumatoid polyneuropathy with rheumatoid arthritis of right hand M Rheumatoid polyneuropathy with rheumatoid arthritis of left hand M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand M Rheumatoid polyneuropathy with rheumatoid arthritis of right hip M Rheumatoid polyneuropathy with rheumatoid arthritis of left hip M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip M Rheumatoid polyneuropathy with rheumatoid arthritis of right knee M Rheumatoid polyneuropathy with rheumatoid arthritis of left knee M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee M Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot M Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot M05.59 Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites M05.60 Rheumatoid arthritis of unspecified site with of other organs and systems M Rheumatoid arthritis of right shoulder with of other organs and systems M Rheumatoid arthritis of left shoulder with of other organs and systems M Rheumatoid arthritis of unspecified shoulder with of other organs and systems M Rheumatoid arthritis of right elbow with of other organs and systems M Rheumatoid arthritis of left elbow with of other organs and systems M Rheumatoid arthritis of unspecified elbow with of other organs and systems M Rheumatoid arthritis of right wrist with of other organs and systems M Rheumatoid arthritis of left wrist with of other organs and systems M Rheumatoid arthritis of unspecified wrist with of other organs and systems M Rheumatoid arthritis of right hand with of other organs and systems M Rheumatoid arthritis of left hand with of other organs and systems M Rheumatoid arthritis of unspecified hand with of other organs and systems M Rheumatoid arthritis of right hip with of other organs and systems
8 M Rheumatoid arthritis of left hip with of other organs and systems M Rheumatoid arthritis of unspecified hip with of other organs and systems M Rheumatoid arthritis of right knee with of other organs and systems M Rheumatoid arthritis of left knee with of other organs and systems M Rheumatoid arthritis of unspecified knee with of other organs and systems M Rheumatoid arthritis of right ankle and foot with of other organs and systems M Rheumatoid arthritis of left ankle and foot with of other organs and systems M Rheumatoid arthritis of unspecified ankle and foot with of other organs and systems M05.69 Rheumatoid arthritis of multiple sites with of other organs and systems M05.70 Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems M Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems M Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems M Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems M Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems M Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems M Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems M Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems M Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems M Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems M Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems M Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems M Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems M Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems
9 M Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems M Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems M Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems M Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems M Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems M Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems M Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems M Rheumatoid arthritis with rheumatoid factor of unspecified ankle and wrist without organ or systems M05.79 Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems M05.80 Other rheumatoid arthritis with rheumatoid factor of unspecified site M Other rheumatoid arthritis with rheumatoid factor of right shoulder M Other rheumatoid arthritis with rheumatoid factor of left shoulder M Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder M Other rheumatoid arthritis with rheumatoid factor of right elbow M Other rheumatoid arthritis with rheumatoid factor of left elbow M Other rheumatoid arthritis with rheumatoid factor of unspecified elbow M Other rheumatoid arthritis with rheumatoid factor of right wrist M Other rheumatoid arthritis with rheumatoid factor of left wrist M Other rheumatoid arthritis with rheumatoid factor of unspecified wrist M Other rheumatoid arthritis with rheumatoid factor of right hand M Other rheumatoid arthritis with rheumatoid factor of left hand M Other rheumatoid arthritis with rheumatoid factor of unspecified hand M Other rheumatoid arthritis with rheumatoid factor of right hip M Other rheumatoid arthritis with rheumatoid factor of left hip M Other rheumatoid arthritis with rheumatoid factor of unspecified hip M Other rheumatoid arthritis with rheumatoid factor of right knee M Other rheumatoid arthritis with rheumatoid factor of left knee
10 M Other rheumatoid arthritis with rheumatoid factor of unspecified knee M Other rheumatoid arthritis with rheumatoid factor of right ankle and foot M Other rheumatoid arthritis with rheumatoid factor of left ankle and foot M Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot M05.89 Other rheumatoid arthritis with rheumatoid factor of multiple sites M05.9 Rheumatoid arthritis with rheumatoid factor, unspecified M06.00 Rheumatoid arthritis without rheumatoid factor, unspecified site M Rheumatoid arthritis without rheumatoid factor, unspecified shoulder M Rheumatoid arthritis without rheumatoid factor, right elbow M Rheumatoid arthritis without rheumatoid factor, left elbow M Rheumatoid arthritis without rheumatoid factor, unspecified elbow M Rheumatoid arthritis without rheumatoid factor, right wrist M Rheumatoid arthritis without rheumatoid factor, left wrist M Rheumatoid arthritis without rheumatoid factor, unspecified wrist M Rheumatoid arthritis without rheumatoid factor, right hand M Rheumatoid arthritis without rheumatoid factor, left hand M Rheumatoid arthritis without rheumatoid factor, unspecified hand M Rheumatoid arthritis without rheumatoid factor, right hip M Rheumatoid arthritis without rheumatoid factor, left hip M Rheumatoid arthritis without rheumatoid factor, unspecified hip M Rheumatoid arthritis without rheumatoid factor, right knee M Rheumatoid arthritis without rheumatoid factor, left knee M Rheumatoid arthritis without rheumatoid factor, unspecified knee M Rheumatoid arthritis without rheumatoid factor, right ankle and foot M Rheumatoid arthritis without rheumatoid factor, left ankle and foot M Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot M06.08 Rheumatoid arthritis without rheumatoid factor, vertebrae M06.09 Rheumatoid arthritis without rheumatoid factor, multiple sites M06.4 Inflammatory polyarthropathy M06.80 Other specified rheumatoid arthritis, unspecified site M Other specified rheumatoid arthritis, right shoulder M Other specified rheumatoid arthritis, left shoulder M Other specified rheumatoid arthritis, unspecified shoulder M Other specified rheumatoid arthritis, right elbow
11 M Other specified rheumatoid arthritis, left elbow M Other specified rheumatoid arthritis, unspecified elbow M Other specified rheumatoid arthritis, right wrist M Other specified rheumatoid arthritis, left wrist M Other specified rheumatoid arthritis, unspecified wrist M Other specified rheumatoid arthritis, right hand M Other specified rheumatoid arthritis, left hand M Other specified rheumatoid arthritis, unspecified hand M Other specified rheumatoid arthritis, right hip M Other specified rheumatoid arthritis, left hip M Other specified rheumatoid arthritis, unspecified hip M Other specified rheumatoid arthritis, right knee M Other specified rheumatoid arthritis, left knee M Other specified rheumatoid arthritis, unspecified knee M Other specified rheumatoid arthritis, right ankle and foot M Other specified rheumatoid arthritis, left ankle and foot M Other specified rheumatoid arthritis, unspecified ankle and foot M06.88 Other specified rheumatoid arthritis, vertebrae M06.89 Other specified rheumatoid arthritis, multiple sites M06.9 Rheumatoid arthritis, unspecified M08.00 Unspecified juvenile rheumatoid arthritis of unspecified site M Unspecified juvenile rheumatoid arthritis, right shoulder M Unspecified juvenile rheumatoid arthritis, left shoulder M Unspecified juvenile rheumatoid arthritis, unspecified shoulder M Unspecified juvenile rheumatoid arthritis, right elbow M Unspecified juvenile rheumatoid arthritis, left elbow M Unspecified juvenile rheumatoid arthritis, unspecified elbow M Unspecified juvenile rheumatoid arthritis, right wrist M Unspecified juvenile rheumatoid arthritis, left wrist M Unspecified juvenile rheumatoid arthritis, unspecified wrist M Unspecified juvenile rheumatoid arthritis, right hand M Unspecified juvenile rheumatoid arthritis, left hand M Unspecified juvenile rheumatoid arthritis, unspecified hand M Unspecified juvenile rheumatoid arthritis, right hip
12 M Unspecified juvenile rheumatoid arthritis, left hip M Unspecified juvenile rheumatoid arthritis, unspecified hip M Unspecified juvenile rheumatoid arthritis, right knee M Unspecified juvenile rheumatoid arthritis, left knee M Unspecified juvenile rheumatoid arthritis, unspecified knee M Unspecified juvenile rheumatoid arthritis, right ankle and foot M Unspecified juvenile rheumatoid arthritis, left ankle and foot M Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot M08.08 Unspecified juvenile rheumatoid arthritis, vertebrae M08.09 Unspecified juvenile rheumatoid arthritis, multiple sites M08.20 Juvenile rheumatoid arthritis with systemic onset, unspecified site M Juvenile rheumatoid arthritis with systemic onset, right shoulder M Juvenile rheumatoid arthritis with systemic onset, left shoulder M Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder M Juvenile rheumatoid arthritis with systemic onset, right elbow M Juvenile rheumatoid arthritis with systemic onset, left elbow M Juvenile rheumatoid arthritis with systemic onset, unspecified elbow M Juvenile rheumatoid arthritis with systemic onset, right wrist M Juvenile rheumatoid arthritis with systemic onset, left wrist M Juvenile rheumatoid arthritis with systemic onset, unspecified wrist M Juvenile rheumatoid arthritis with systemic onset, right hand M Juvenile rheumatoid arthritis with systemic onset, left hand M Juvenile rheumatoid arthritis with systemic onset, unspecified hand M Juvenile rheumatoid arthritis with systemic onset, right hip M Juvenile rheumatoid arthritis with systemic onset, left hip M Juvenile rheumatoid arthritis with systemic onset, unspecified hip M Juvenile rheumatoid arthritis with systemic onset, right knee M Juvenile rheumatoid arthritis with systemic onset, left knee M Juvenile rheumatoid arthritis with systemic onset, unspecified knee M Juvenile rheumatoid arthritis with systemic onset, right ankle and foot M Juvenile rheumatoid arthritis with systemic onset, left ankle and foot M Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot M08.28 Juvenile rheumatoid arthritis with systemic onset, vertebrae M08.29 Juvenile rheumatoid arthritis with systemic onset, multiple sites
13 M08.3 Juvenile rheumatoid polyarthritis (seronegative) M08.40 Pauciarticular juvenile rheumatoid arthritis, unspecified site M Pauciarticular juvenile rheumatoid arthritis, right shoulder M Pauciarticular juvenile rheumatoid arthritis, left shoulder M Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder M Pauciarticular juvenile rheumatoid arthritis, right elbow M Pauciarticular juvenile rheumatoid arthritis, left elbow M Pauciarticular juvenile rheumatoid arthritis, unspecified elbow M Pauciarticular juvenile rheumatoid arthritis, right wrist M Pauciarticular juvenile rheumatoid arthritis, left wrist M Pauciarticular juvenile rheumatoid arthritis, unspecified wrist M Pauciarticular juvenile rheumatoid arthritis, right hand M Pauciarticular juvenile rheumatoid arthritis, left hand M Pauciarticular juvenile rheumatoid arthritis, unspecified hand M Pauciarticular juvenile rheumatoid arthritis, right hip M Pauciarticular juvenile rheumatoid arthritis, left hip M Pauciarticular juvenile rheumatoid arthritis, unspecified hip M Pauciarticular juvenile rheumatoid arthritis, right knee M Pauciarticular juvenile rheumatoid arthritis, left knee M Pauciarticular juvenile rheumatoid arthritis, unspecified knee M Pauciarticular juvenile rheumatoid arthritis, right ankle and foot M Pauciarticular juvenile rheumatoid arthritis, left ankle and foot M Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot M08.48 Pauciarticular juvenile rheumatoid arthritis, vertebrae M08.80 Other juvenile arthritis, unspecified site M Other juvenile arthritis, right shoulder M Other juvenile arthritis, left shoulder M Other juvenile arthritis, unspecified shoulder M Other juvenile arthritis, right elbow M Other juvenile arthritis, left elbow M Other juvenile arthritis, unspecified elbow M Other juvenile arthritis, right wrist M Other juvenile arthritis, left wrist M Other juvenile arthritis, unspecified wrist
14 M Other juvenile arthritis, right hand M Other juvenile arthritis, left hand M Other juvenile arthritis, unspecified hand M Other juvenile arthritis, right hip M Other juvenile arthritis, left hip M Other juvenile arthritis, unspecified hip M Other juvenile arthritis, right knee M Other juvenile arthritis, left knee M Other juvenile arthritis, unspecified knee M Other juvenile arthritis, right ankle and foot M Other juvenile arthritis, left ankle and foot M Other juvenile arthritis, unspecified ankle and foot M08.88 Other juvenile arthritis, other specified site M08.89 Other juvenile arthritis, multiple sites M08.90 Juvenile arthritis, unspecified, unspecified site M Juvenile arthritis, unspecified, right shoulder M Juvenile arthritis, unspecified, left shoulder M Juvenile arthritis, unspecified, unspecified shoulder M Juvenile arthritis, unspecified, right elbow M Juvenile arthritis, unspecified, left elbow M Juvenile arthritis, unspecified, unspecified elbow M Juvenile arthritis, unspecified, right wrist M Juvenile arthritis, unspecified, left wrist M Juvenile arthritis, unspecified, unspecified wrist M Juvenile arthritis, unspecified, right hand M Juvenile arthritis, unspecified, left hand M Juvenile arthritis, unspecified, unspecified hand M Juvenile arthritis, unspecified, right hip M Juvenile arthritis, unspecified, left hip M Juvenile arthritis, unspecified, unspecified hip M Juvenile arthritis, unspecified, right knee M Juvenile arthritis, unspecified, left knee M Juvenile arthritis, unspecified, unspecified knee M Juvenile arthritis, unspecified, right ankle and foot
15 M Juvenile arthritis, unspecified, left ankle and foot M Juvenile arthritis, unspecified, unspecified ankle and foot M08.98 Juvenile arthritis, unspecified, vertebrae M08.99 Juvenile arthritis, unspecified, multiple sites R59.0 Localized enlarged lymph nodes R59.1 Generalized enlarged lymph nodes R59.9 Enlarged lymph nodes, unspecified Review Date Revisions Effective Date 09/2014 New criteria adopted from ICORE guidelines 09/30/ /2015 Updated with ICD-10 codes, updated references; 10/28/2015 deleted ICD-9 codes, updated Magellan criteria 02/2016 Updated ICD-10 codes with Magellanin compliance with CMS changes 02/24/2016 References: Actemra [package insert]. South San Francisco, CA; Genentech, Inc; November Accessed November 2015 Singh JA, Furst DE, Bharat A, et al update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) May;64(5): Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: Beukelman T, Patkar NM, Saag KG, et al American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) Apr;63(4): Ringold S, Weiss PF, Beukelman T, et al update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum Oct;65(10): DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) Jul;64(7):
DISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR RHEUMATOID ARTHRITIS
DISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR RHEUMATOID ARTHRITIS APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE NCQA APPROVED CODES HEDIS
More informationRheumatology ICD-10 documentation
Rheumatology documentation Seven key impacts to documentation 1. Disease or disorder site 2. Acuity and/or encounter status of treatment 3. Etiology, causative agent, or disease type and injury/ poisoning
More informationCytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists
MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must
More informationRheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion
Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment
More informationRoche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
Media Release Basel, 6 June 2012 Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) September 2014 Review date: September 2017 Bulletin 203: Tocilizumab (subcutaneous) in combination with methotrexate or as monotherapy for the treatment
More informationMedical Policy Anti-CCP Testing for Rheumatoid Arthritis
Medical Policy Anti-CCP Testing for Rheumatoid Arthritis Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References Authorization
More informationSECTION 3. Criteria for Special Authorization of Select Drug Products. Section 3 Criteria for Special Authorization of Select Drug Products
SECTION 3 Criteria for Special Authorization of Select Drug Products Section 3 Criteria for Special Authorization of Select Drug Products CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS The
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationMEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion ACTEMRA (AC-TEM-RA) (tocilizumab) Injection, Solution for Subcutaneous Administration Read this Medication Guide before
More informationACTEMRA (tocilizumab) injection, for intravenous use injection, for subcutaneous use Initial U.S. Approval: 2010
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. ACTEMRA (tocilizumab)
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
November 1, 2014 Bulletin #150 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary New Exception Drug Status (EDS) Listings Effective November 1, 2014
More informationEvidence-based Management of Rheumatoid Arthritis (2009)
CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance
More informationRheumatoid Arthritis Information
Rheumatoid Arthritis Information Definition Rheumatoid arthritis (RA) is a long-term disease that leads to inflammation of the joints and surrounding tissues. It can also affect other organs. Alternative
More informationACTEMRA Lab Monitoring Guide 1 For DMARD-IR patients with moderate to severe RA
ath,, interrupt er p infusion es including ld ACTEMRA Lab Monitoring Guide 1 For DMARD-IR patients with moderate to severe RA eving an d laboratory n training and death, permanently s, platelets, d Indication
More informationDrug Therapy Guidelines: Humira (adalimumab)
Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:
More informationCurrent Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists
Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and
More informationE08.621 Diabetes mellitus due to underlying condition with foot ulcer E09.621 Drug or chemical induced diabetes mellitus with foot ulcer E10.10 Type 1 diabetes mellitus with ketoacidosis without coma E10.11
More informationArthritis in Children: Juvenile Rheumatoid Arthritis By Kerry V. Cooke
Reading Comprehension Read the following essay on juvenile rheumatoid arthritis. Then use the information in the text to answer the questions that follow. Arthritis in Children: Juvenile Rheumatoid Arthritis
More informationRHEUMATOLOGY ICD-10 CROSSWALK
RHEUMATOLOGY ICD-10 CROSSWALK ICD is revised periodically and is currently in its tenth edition and will be implemented in the United States on October 1, 2015. There is an annual minor update and three-yearly
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd
ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationHow To Take Methotrexate By Injection
How To Take Methotrexate By Injection 1 how long does it take for methotrexate to work for abortion 2 methotrexate 15 mg hair loss 3 methotrexate injection dosage for rheumatoid arthritis 4 order methotrexate
More informationImmune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association
Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell
More informationIssue date: August 2010
Issue date: August 2010 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Part review of NICE technology appraisal
More informationCytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
More informationCytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
More informationABOUT RHEUMATOID ARTHRITIS
MEDIA BACKGROUNDER ABOUT RHEUMATOID ARTHRITIS Rheumatoid arthritis (RA) is a type of arthritis (chronic inflammatory polyarthritis) that typically affects hands and feet, although any joint in the body
More informationpåçííáëü=jéçáåáåéë=`çåëçêíáìã==
påçííáëü=jéçáåáåéë=`çåëçêíáìã== adalimumab 40mg pre-filled syringe for subcutaneous injection (Humira ) No. (218/05) Abbott New indication: treatment of active and progressive psoriatic arthritis in adults
More informationMethods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice
Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice Gu NY 1, Huang XY 2, Globe D 2, Fox KM 3 1 University of Southern California,
More informationto Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.
2.0 Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Adalimumab (HUMIRA) (For National Authority Use Only) Name of Active Ingredient: Adalimumab Title
More informationTop 50 ICD-10-Codes Description ICD-9-CM Code ICD-10-CM Code 724.5 727.3
Description ICD-9-CM Code ICD-10-CM Code Backache unspecified 724.5 M54.89 Other dorsalgia Excludes1: o dorsalgia in thoracic region (M54.6) o low back pain (M54.5) M54.9 Dorsalgia, unspecified Other bursitis
More informationDisease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment
A WHITE PAPER BY Disease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment Increased adherence rates deliver improved outcomes for patients FALL 2010 The Benefits of DTM for Rheumatoid Arthritis
More informationCLINICAL POLICY Department: Medical Management Document Name: Rheumatoid & Juvenile Arthritis and Ankylosing Spondylitis Treatments
Page: 1 of 18 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationTreatment of Severe Rheumatoid Arthritis
Treatment of Severe Rheumatoid Arthritis Zhanguo Li Department of Rheumatology and Immunology, People s Hospital Beijing University Medical School, China Contents Background Challenges Treatment strategies
More informationRheumatoid Arthritis. Disease RA Final.indd 2 15. 6. 10. 11:23
Rheumatoid Arthritis Disease RA Final.indd 2 15. 6. 10. 11:23 Understanding what to expect can help you prepare for your transition into treatment. Rheumatoid Arthritis What You Need To Know About Rheumatoid
More informationM05.9 Rheumatoid arthritis with rheumatoid factor, unspecified M06.00 Rheumatoid arthritis without rheumatoid factor, unspecified site M06.
Rheumatology ICD-9 ICD-10 V58.69 Z79.3 Long term (current) use of hormonal contraceptives Z79.891 Long term (current) use of opiate analgesic Z79.899 Other long term (current) drug therapy 714.0 M05.40
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationMorgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1
Morgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1 Faculty of Pharmacy and Pharmaceutical Sciences, 2 Faciluty of Medicine and Dentistry, 3 School
More informationRheumatoid Arthritis
Rheumatoid Arthritis While rheumatoid arthritis (RA) has long been feared as one of the most disabling types of arthritis, the outlook has dramatically improved for many newly diagnosed patients. Certainly
More informationMedicines for Rheumatoid. Arthritis. A Review of the Research for Adults
Medicines for Rheumatoid Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this summary is for you if: Your doctor* has told you that you have rheumatoid (pronounced
More informationAntares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS. Paul
Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS Paul Antares Mission: To develop and commercialize self-administered parenteral medicines
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More informationSystemic Juvenile Adiopathic Arthritis: Treatment Options 15. Alexei A. Grom, MD Cincinnati Children s Hospital Medical Center
Systemic Juvenile Adiopathic Arthritis: Treatment Options 15 Alexei A. Grom, MD Cincinnati Children s Hospital Medical Center Disclosures NIH grants AR059049, AR048929 Consulting fees Novartis, Roche,
More informationDISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY
ORIGINAL ARTICLES DISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY Teodora Serban 1,2, Iulia Satulu 2, Oana Vutcanu 2, Mihaela Milicescu 1,2, Carina Mihai 1,2, Mihai Bojinca 1,2, Victor
More informationDIVISION OF RHEUMATOLOGY DEPARTMENT OF MEDICINE UNIVERSITY OF WESTERN ONTARIO POSTGRADUATE EDUCTION ORTHOPAEDIC OFF-SERVICE GOALS & OBJECTIVES
DIVISION OF RHEUMATOLOGY DEPARTMENT OF MEDICINE UNIVERSITY OF WESTERN ONTARIO POSTGRADUATE EDUCTION ORTHOPAEDIC OFF-SERVICE GOALS & OBJECTIVES GOAL #1 develop the ability to order and understand interpretation
More information5.07.09. Aubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)
More informationPatient Input Information Clinical Trials Outcomes Common Drug Review
CDEC FINAL RECOMMENDATION USTEKINUMAB (Stelara Janssen Inc.) Indication: Psoriatic Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that ustekinumab not be listed at the submitted
More informationRheumatoid Arthritis: Constantly Evolving Treatment Approaches
Rheumatoid Arthritis: Constantly Evolving Treatment Approaches Jody Garry, Pharm.D. Primary Care Pharmacy Resident VA Medical Center - Iowa City Presentation Overview Pathophysiology & epidemiology Diagnostic
More informationI. INCLUSION AND EXCLUSION CRITERIA
Page 1 of 5 I. INCLUSION AND EXCLUSION CRITERIA INCLUSION CRITERIA Yes No 1. Patient is diagnosed with according to the American College of Rheumatology 1987 revised criteria. 2. All 4 grandparents are
More information9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance
Disclosure Statement of Financial Interest New Therapies for Asthma Including Omalizumab and Anti-Cytokine Therapies Marsha Dangler, PharmD, BCACP Clinical Pharmacy Specialist James H. Quillen VA Medical
More informationRemicade (infliximab)
DRUG POLICY Remicade (infliximab) Policy Number: 2015D004P Effective Date: 12/1/2015 Table of Contents Page COVERAGE RATIONALE... 1 BENEFIT CONSIDERATIONS... 3 BACKGROUND... 3 CLINICAL EVIDENCE... 4 U.S.
More information-- OTREXUP : The First Proprietary Product Featuring the VIBEX Medi-Jet Technology, an Easy-to-Use, Patient Friendly Auto Injector--
OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA A NEW TREATMENT FOR ADULTS WITH RHEUMATOID ARTHRITIS, CHILDREN WITH POLYARTICULAR IDIOPATHIC ARTHRITIS, AND ADULTS WITH PSORIASIS -- OTREXUP : The First
More informationDr Sarah Levy Consultant Rheumatology Croydon University Hospital
Dr Sarah Levy Consultant Rheumatology Croydon University Hospital Contents Definition/ epidemiology Diagnosis Importance of early diagnosis/ treatment Guidelines Evidence based treatment protocol Current
More informationInformation on Rheumatoid Arthritis
Information on Rheumatoid Arthritis Table of Contents About Rheumatoid Arthritis 1 Definition 1 Signs and symptoms 1 Causes 1 Risk factors 1 Test and diagnosis 2 Treatment options 2 Lifestyle 3 References
More informationRHEUMATOID ARTHRITIS. Dr Bruce Kirkham Rheumatology Clinical Lead
RHEUMATOID ARTHRITIS Dr Bruce Kirkham Rheumatology Clinical Lead RHEUMATOID ARTHRITIS (RA) RA is a common disease: 0.8 per cent of the population RA more common in females: female to male ratio 3:1 RA
More informationMedicines for Psoriatic Arthritis. A Review of the Research for Adults
Medicines for Psoriatic Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have psoriatic (pronounced
More informationImprovement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy
Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy R Adams 1, Ct Ng 2, A Gibbs 2, L Tilson 1, D Veale 2, B Bresnihan 2, O FitzGerald 2, M Barry 1 1. National Centre for
More informationRheumatology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Rheumatology
Rheumatology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Rheumatology Chapter 12: Diseases of Skin and Subcutaneous Tissue ICD-10-CM introduces a new term, androgenic alopecia. Pressure
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationRheumatoid Arthritis:
Rheumatoid Arthritis Update 2014 Mark Hulsey, MD FACR Rheumatoid Arthritis Key Features Symptoms >6 weeks duration Often lasts the remainder of the patient s life Inflammatory synovitis Palpable synovial
More informationSpeaking Plainly. Biologic treatment options for rheumatoid arthritis
in association with Plain English Campaign Speaking Plainly Biologic treatment options for rheumatoid arthritis A guide to help healthcare professionals talking to patients with rheumatoid arthritis Foreword
More informationAutoimmune Diseases More common than you think Randall Stevens, MD
Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system
More informationShared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)
More informationA New Era in Rheumatoid Arthritis Treatment
A New Era in Rheumatoid Arthritis Treatment Jill C. Costello, MD; Paul B. Halverson, MD ABSTRACT Rheumatoid Arthritis (RA) is a systemic autoimmune disease that primarily manifests as a chronic symmetric
More information2015 HCPCS CODE ADDITIONS
2015 HCPCS CODE ADDITIONS Bolded Codes Bolded codes indicate notation of special billing policy. Chemotherapy A9606, C9442, J9267, J9301 A9606 Billing is for males only. C9442 Belinostat is used for the
More informationPatient Assistance Application for HUMIRA (adalimumab)
The AbbVie Patient Assistance Foundation provides AbbVie medicines at no cost to patients experiencing financial difficulties. Eligible patients typically have no healthcare coverage for the requested
More informationMethotrexate Dose For Juvenile Rheumatoid Arthritis
Methotrexate Dose For Juvenile Rheumatoid Arthritis should i take methotrexate for my ra methotrexate 50 mg/ml methotrexate sodium 2.5mg tablets what is the usual dosage of methotrexate for ra methotrexate
More informationRheumatoid Arthritis
Rheumatoid Arthritis Carole Callaghan Principal Pharmacist NHS Lothian Aim To update pharmacists on the current management of rheumatoid arthritis and explore ways to implement pharmaceutical care for
More informationEtanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Etanercept, infliximab and adalimumab for the treatment of Issued: August 2010 guidance.nice.org.uk/ta199 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to
More informationPCPI Approved July 2008
MEASURE STATUS: FINAL - PCPI Approved National Committee for Quality Assurance/Physician Consortium for Performance Improvement /American College of National Committee for Quality Assurance (NCQA) Physician
More informationAssessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional Survey
DOI 10.1007/s40744-015-0011-1 ORIGINAL RESEARCH Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional Survey Dana B. DiBenedetti. Xiaolei Zhou. Maria Reynolds. Sarika Ogale. Jennie
More informationStandard of care for RA in SA 2013
Standard of care for RA in SA 2013 Background Rheumatoid arthritis (RA) is a chronic inflammatory disease, which if treated inadequately leads to irreversible joint damage, resulting in deformities, disability
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationGlobal Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)
Brochure More information from http://www.researchandmarkets.com/reports/2693611/ Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018) Description: The report titled 'Global Rheumatoid
More informationArthritis & Rheumatism
ARTHRITIS & RHEUMATISM Vol. 65, No. 10, October 2013, pp 2499 2512 DOI 10.1002/art.38092 2013, American College of Rheumatology SPECIAL ARTICLE Arthritis & Rheumatism An Official Journal of the American
More information5.04.20. Perjeta. Perjeta (pertuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.20 Subject: Perjeta Page: 1 of 5 Last Review Date: June 19, 2015 Perjeta Description Perjeta (pertuzumab)
More informationCriteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps)
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 05/15 Revision Date(s): 05/2015 Developed By: Medical Criteria Committee 06/24/2015 External Infusion Insulin Pumps Page 1 of
More informationRheumatoid Arthritis. GP workshop 15 January 2011
Rheumatoid Arthritis GP workshop 15 January 2011 Case 1 A 72 year old Malay woman with RA comes for routine follow up. She feels generally unwell in the last 5 days. Appetite is fair. Her joints are fine.
More informationRheumatology. Rheumatoid Arthritis
Rheumatology Rheumatoid Arthritis The Rheumatology service specialises in the diagnosis and treatment of diseases affecting the musculoskeletal system. Other than providing inpatient and outpatient consultation,
More informationOsteoporosis and Arthritis: Two Common but Different Conditions
and : Two Common but Different Conditions National Institutes of Health and Related Bone Diseases ~ National Resource Center 2 AMS Circle Bethesda, MD 20892 3676 Tel: 800 624 BONE or 202 223 0344 Fax:
More informationA LTCI Approach to Managing Rheumatoid Arthritis
A LTCI Approach to Managing Rheumatoid Arthritis A bit of Science, a bit of Art, a lot of Perseverance... Stephen K. Holland, MD Senior Vice President & Medical Director Long Term Care Group, Inc. Long
More informationArthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis
Arthritis and Rheumatology Clinics of Kansas Patient Education Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis Introduction: For as long as scientists have studied rheumatic disease,
More informationThe Janssen Biotech Support System. Getting patients started on STELARA
The Janssen Biotech Support System Getting patients started on STELARA 3 STEPS after identifying patients appropriate for STELARA (ustekinumab) STEP 1: Determine the correct dose STELARA is administered
More informationGuidelines for the Pharmaceutical Management of Rheumatoid Arthritis Swedish Society of Rheumatology, April 14, 2011
Guidelines for the Pharmaceutical Management of Rheumatoid Arthritis Swedish Society of Rheumatology, April 14, 2011 Working party: Eva Baecklund, Helena Forsblad d Elia, Carl Turesson Background Our purpose
More informationMeasuring and Improving the Quality of Care for Patients With. Rheumatoid Arthritis
Measuring and Improving the Quality of Care for Patients With Rheumatoid Arthritis section 1 reporting Measuring and Improving the Quality of Care for Patients With Rheumatoid Arthritis An estimated 1.3
More informationPain is the most common complaint for which most patients seek rheumatologic. Chronic Pain From Rheumatoid Arthritis
PRINTER-FRIENDLY VERSION AVAILABLE AT PAINMEDICINENEWS.COM Chronic Pain From Rheumatoid Arthritis ROLAND STAUD, MD Director, Musculoskeletal Pain Research Professor University of Florida College of Medicine
More informationOverview of Rheumatology
Overview of Rheumatology Griffin Hospital Mini Med School Stephen Moses, MD Valley Medical Associates 135 Division St. Ansonia, CT 06401 203.735.9354 Topics I. Anatomy of a Joint II. Osteoarthritis III.
More informationRheumatoid Arthritis www.arthritis.org.nz
Rheumatoid Arthritis www.arthritis.org.nz Did you know? RA is the second most common form of arthritis Approximately 40,000 New Zealanders have RA RA can occur at any age, but most often appears between
More informationRheumatoid Arthritis. How are joints in the body designed?
Rheumatoid Arthritis How are joints in the body designed? There are more than 100 joints that connect the body s 206 bones. These joints allow us to move the way we do when we walk to work, throw a ball
More informationRheumatoid Arthritis: Diagnosis, Management and Monitoring
Rheumatoid Arthritis: Diagnosis, Management and Monitoring Effective Date: September 30, 2012 Scope This guideline is intended to aid in early recognition, intervention and management of patients with
More informationMaster Thesis in Medicine
RISK OF INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB IN CLINICAL PRACTICE Master Thesis in Medicine Joyce Åkerlund Supervisor: Catharina Lindholm, MD, PhD, Associate Professor Department
More informationRheumatoid Arthritis. What is rheumatoid arthritis? Understanding joints. What causes rheumatoid arthritis?
Page 1 of 6 Rheumatoid Arthritis Rheumatoid arthritis causes inflammation, pain, and swelling of joints. In time, affected joints typically become damaged. The severity can vary from mild to severe. Treatments
More informationRecognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis
White Paper March 2013 Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis Catherine Augustyn, Brigham Walker, and Thomas F. Goss, PharmD Boston Healthcare Associates, Inc., Boston,
More informationsubcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP
More informationPage 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective Date: 10/1/2013
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Alimta (pemetrexed) Page 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective
More informationRheumatoid arthritis: diagnosis, treatment and prognosis. Dr David D Cruz MD FRCP Consultant Rheumatologist
Rheumatoid arthritis: diagnosis, treatment and prognosis Dr David D Cruz MD FRCP Consultant Rheumatologist The Louise Coote Lupus Unit St Thomas Hospital London AMUS meeting London 7 th March 2012 Disclosures
More information